Cited by 149Lymphoma Diagnosis and TreatmentMonoclonal and Polyclonal Antibodies ResearchImmune Cell Function and Interaction

The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.

Treatment of Refractory Hodgkin's Disease With an Anti-CD16/CD30 Bispecific Antibody

Hartmann, Frank, Renner, Christoph, Jung, Wolfram, Deisting, Christina, Juwana, Marietta, Eichentopf, Bertram, Kloft, Michael, Pfreundschuh, Michael·1997·Blood

DOI 10.1182/blood.v89.6.2042

Open this paper in CoChat — free account

Abstract

Fifteen patients with refractory Hodgkin's disease were treated in a phase I/II trial with the natural killer (NK)-cell–activating bispecific monoclonal antibody HRS-3/A9, which is directed against the Fcγ-receptor III (CD16 antigen) and the Hodgkin's-associated CD30 antigen, respectively. Median counts of NK cells and of all lymphocyte subsets were considerably decreased in the patients before therapy. HRS-3/A9 was administered 4 times every 3 to 4 days, starting with 1 mg/m2. The treatment was well tolerated, and the maximum tolerated dose was not reached at 64 mg/m2, the highest dose administered because of the limited amounts of HRS-3/A9 available. Side effects were rare and consisted of fever, pain in involved lymph nodes, and a maculopapulous rash. A total of 9 patients developed human antimouse Ig antibodies, and 4 patients developed an allergic reaction after attempted retreatment. A total of 1 complete and 1 partial remission (lasting 16 and 3 months, respectively), 3 minor responses (1 to 11+ months), and 1 mixed response were achieved. There was no clear-cut dose-side effect or dose-response correlation. Our results encourage further clinical trials with this novel immunotherapeutic approach and emphasize the necessity to reduce the immunogenicity of the murine bispecific antibodies.

Integrity signals

Registry

Crossref · 10.1182/blood.v89.6.2042

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

The expression of the Hodgkin's disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells
Stein, H., Mason, D., Gerdes, J., O'Connor, N., Wainscoat, J. S., Pallesen, G., Gatter, K. C., Falini, B., Delsol, G., Lemke, H., et al. (1985) · Blood · doi:10.1182/blood.v66.4.848.848 · Cited by 1,849
"Diabodies": small bivalent and bispecific antibody fragments.
Holliger, P., Prospero, T. D., & Winter, G. P. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.14.6444 · Cited by 882
The expression of the Hodgkin's disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells
Stein, H., Mason, D., Gerdes, J., et al. (1985) · Blood · doi:10.1182/blood.v66.4.848.bloodjournal664848 · Cited by 717
Hybrid hybridomas and their use in immunohistochemistry
Milstein, C., & Cuello, A. C. (1983) · Nature · doi:10.1038/305537a0 · Cited by 525
A small bispecific antibody construct expressed as a functional single-chain molecule with high tumor cell cytotoxicity.
Mack, M., Riethmüller, G., & Kufer, P. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.15.7021 · Cited by 351
Selective modulation of human natural killer cells in vivo after prolonged infusion of low dose recombinant interleukin 2.
Caligiuri, M. A., Murray, C., Robertson, M. J., Wang, E. S., Cochran, K., Cameron, C. A., Schow, P. W., Ross, M. E., Klumpp, T. R., & Soiffer, R. J. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116161 · Cited by 267
Preliminary trial of specific targeting therapy against malignant glioma
Nitta, T., Yagita∥, H., Okumura, K., Sato, K., & Ishii, S. (1990) · The Lancet · doi:10.1016/0140-6736(90)90205-j · Cited by 235
Regression of Advanced Ovarian Carcinoma by Intraperitoneal Treatment With Autologous TLymphocytes Retargeted by a Bispecific Monoclonal Antibody
Canevari, S., Stoter, G., Arienti, F., Bolis, G., Colnaghi, M. I., Re, E. D., Eggermont, A. M. M., Goey, S. H., Gratama, J. W., Lamers, C. H. J., et al. (1995) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/87.19.1463 · Cited by 187
Phase Ia/Ib trial of bispecific antibody MDX-210 in patients with advanced breast or ovarian cancer that overexpresses the proto-oncogene HER-2/neu.
Valone, F. H., Kaufman, P. A., Guyre, P. M., Lewis, L. D., Memoli, V. A., Deo, Y. M., Graziano, R. F., Fisher, J. L., Meyer, L. A., & Mrozek-Orlowski, M. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.9.2281 · Cited by 180
Cure of Xenografted Human Tumors by Bispecific Monoclonal Antibodies and Human T Cells
Renner, C., Jung, W. E., Şahin, U., Denfeld, R. W., Pohl, C., Trümper, L. H. P., Hartmann, F., Diehl, V., van Lier, R. A. W., & Pfreundschuh, M. G. (1994) · Science · doi:10.1126/science.8171337 · Cited by 156
Self-citation

Show all 29 references

Research works printed but not linked: 1

Weiner, 1995, Phase I Trial of 2B1, a bispecific monoclonal antibody targeting c-erB-2 and FcγRIII., Cancer Res, 55, 4586

Sorted by citations

Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial
Schmitz, N., Pfistner, B., Sextro, M., Sieber, M., Carella, A. M., Haenel, M., Boissevain, F., Zschaber, R., Müller, P. E., Kirchner, H. H., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08938-9 · Cited by 1,134
Targeting natural killer cells in cancer immunotherapy
Guillerey, C., Huntington, N. D., & Smyth, M. J. (2016) · Nature Immunology · doi:10.1038/ni.3518 · Cited by 1,081
A recombinant bispecific single-chain antibody, CD19 × CD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes
Löffler, A., Kufer, P., Lutterbüse, R., Zettl, F., Daniel, P. T., Schwenkenbecher, J. M., Riethmüller, G., Dörken, B., & Bargou, R. C. (2000) · Blood · doi:10.1182/blood.v95.6.2098 · Cited by 445
The IgG Fc receptor family
Gessner, J. E., Heiken, H., Tamm, A., & Schmidt, R. E. (1998) · Annals of Hematology · doi:10.1007/s002770050396 · Cited by 410
Bispecific antibodies for cancer therapy: The light at the end of the tunnel?
Chames, P., & Baty, D. (2009) · mAbs · doi:10.4161/mabs.1.6.10015 · Cited by 336
Understanding CD30 biology and therapeutic targeting: a historical perspective providing insight into future directions
van der Weyden, C., Pileri, S. A., Feldman, A. L., Whisstock, J. C., & Prince, H. M. (2017) · Blood Cancer Journal · doi:10.1038/bcj.2017.85 · Cited by 249
Construction and characterisation of a functional CD19 specific single chain Fv fragment for immunotherapy of B lineage leukaemia and lymphoma
Nicholson, I., Lenton, K. A., Little, D. J., Decorso, T., Lee, F.-T., Scott, A. M., Zola, H., & Hohmann, A. W. (1997) · Molecular Immunology · doi:10.1016/s0161-5890(97)00144-2 · Cited by 227
Challenges and strategies for next-generation bispecific antibody-based antitumor therapeutics
Li, H., Saw, P. E., & Song, E. (2020) · Cellular and Molecular Immunology · doi:10.1038/s41423-020-0417-8 · Cited by 205
Bispecific T-cell engagers: Towards understanding variables influencing the in vitro potency and tumor selectivity and their modulation to enhance their efficacy and safety
Ellerman, D. A. (2018) · Methods · doi:10.1016/j.ymeth.2018.10.026 · Cited by 200
Bispecific antibody based therapeutics: Strengths and challenges
Thakur, A. B., Huang, M. T. F., & Lum, L. G. (2018) · Blood Reviews · doi:10.1016/j.blre.2018.02.004 · Cited by 187
Generation of BiKEs and TriKEs to Improve NK Cell-Mediated Targeting of Tumor Cells
Felices, M., Lenvik, T. R., Davis, Z., Miller, J. S., & Vallera, D. A. (2016) · Methods in molecular biology · doi:10.1007/978-1-4939-3684-7_28 · Cited by 171
A novel tetravalent bispecific TandAb (CD30/CD16A) efficiently recruits NK cells for the lysis of CD30+tumor cells
Reusch, U., Burkhardt, C., Fucek, I., Gall, F. L., Gall, M. L., Hoffmann‐Sommergruber, K., Knackmuss, S. H. J., Kiprijanov, S. M., Little, M., & Zhukovsky, E. A. (2014) · mAbs · doi:10.4161/mabs.28591 · Cited by 162
A revival of bispecific antibodies
Kufer, P., Lutterbüse, R., & Baeuerle, P. A. (2004) · Trends in Biotechnology · doi:10.1016/j.tibtech.2004.03.006 · Cited by 157
Efficient elimination of chronic lymphocytic leukaemia B cells by autologous T cells with a bispecific anti-CD19/anti-CD3 single-chain antibody construct
Löffler, A., Gruen, M., Wuchter, C., Schriever, F., Kufer, P., Dreier, T., Hanakam, F., Baeuerle, P. A., Bommert, K., Karawajew, L., et al. (2003) · Leukemia · doi:10.1038/sj.leu.2402890 · Cited by 151
Developments and Challenges for mAb-Based Therapeutics
Goswami, S., Wang, W., Arakawa, T., & Ohtake, S. (2013) · Antibodies · doi:10.3390/antib2030452 · Cited by 144
Natural Killer Cells in Cancer Immunotherapy
Miller, J. S., & Lanier, L. L. (2018) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030518-055653 · Cited by 145
Natural killer cells unleashed: Checkpoint receptor blockade and BiKE/TriKE utilization in NK-mediated anti-tumor immunotherapy
Davis, Z., Vallera, D. A., Miller, J. S., & Felices, M. (2017) · Seminars in Immunology · doi:10.1016/j.smim.2017.07.011 · Cited by 141
Immunotherapeutic perspective for bispecific antibodies
van Spriel, A. B., van Ojik, H. H., & van de Winkel, J. G. J. (2000) · Immunology Today · doi:10.1016/s0167-5699(00)01659-5 · Cited by 133
Autotransplants for Hodgkin's disease in first relapse or second remission: a report from the autologous blood and marrow transplant registry (ABMTR)
Lazarus, H., Loberiza, F. R., Zhang, M.-J., Armitage, J. O., Ballen, K., Bashey, A., Bolwell, B., Burns, L., Freytes, C. O., Gale, R., et al. (2001) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1702796 · Cited by 117
Treatment of Refractory Hodgkin's Lymphoma Patients With an Iodine-131–Labeled Murine Anti-CD30 Monoclonal Antibody
Schnell, R., Dietlein, M., Staak, J. O., Borchmann, P., Schomaecker, K., Fischer, T. H., Eschner, W., Hansen, H. P., Morschhauser, F., Schicha, H., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.09.098 · Cited by 116
AFM13: a first-in-class tetravalent bispecific anti-CD30/CD16A antibody for NK cell-mediated immunotherapy
Wu, J., Fu, J., Zhang, M., & Liu, D. (2015) · Journal of Hematology & Oncology · doi:10.1186/s13045-015-0188-3 · Cited by 117
Hodgkin lymphoma
Gobbi, P. G., Ferreri, A. J. M., Ponzoni, M., & Levis, A. (2012) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2012.07.002 · Cited by 121
Rescue of Impaired NK Cell Activity in Hodgkin Lymphoma With Bispecific Antibodies In Vitro and in Patients
Reiners, K. S., Keßler, J., Sauer, M., Rothe, A., Hansen, H. P., Reusch, U., Hucke, C., Koehl, U., Dürkop, H., Engert, A., et al. (2013) · Molecular Therapy · doi:10.1038/mt.2013.14 · Cited by 118
Phase 1 trial of the novel bispecific molecule H22xKi-4 in patients with refractory Hodgkin lymphoma
Borchmann, P., Schnell, R., Fuss, I., Manzke, O., Davis, T. A., Lewis, L. D., Behnke, D., Wickenhauser, C., Schiller, P., Diehl, V., et al. (2002) · Blood · doi:10.1182/blood-2001-12-0295 · Cited by 113
Anti-CD3 × Anti-Epidermal Growth Factor Receptor (EGFR) Bispecific Antibody Redirects T-Cell Cytolytic Activity to EGFR-Positive Cancers In vitro and in an Animal Model
Reusch, U., Sundaram, M., Davol, P. A., Olson, S. D., Davis, J. B., Demel, K. C., Nissim, J., Rathore, R., Liu, P. Y., & Lum, L. G. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1855 · Cited by 106
Anti-CD16/CD30 bispecific antibody treatment for Hodgkin's disease: role of infusion schedule and costimulation with cytokines.
Hartmann, F., Renner, C., Jung, W. E., Costa, L. M. D., Tembrink, S., Held, G., Sek, A., König, J., Bauer, S., Kloft, M., et al. (2001) · PubMed · Cited by 99
Self-citation
Early lymphocyte recovery post‐autologous haematopoietic stem cell transplantation is associated with better survival in Hodgkin's disease
Porrata, L. F., Inwards, D. J., Micallef, I. N., Ansell, S. M., Geyer, S. M., & Markovic, S. N. (2002) · British Journal of Haematology · doi:10.1046/j.1365-2141.2002.03478.x · Cited by 96
Synergistic Antitumor Effect of Bispecific CD19 × CD3 and CD19 × CD16 Diabodies in a Preclinical Model of Non-Hodgkin’s Lymphoma
Kipriyanov, S. M., Cochlovius, B., Schäfer, H., Moldenhauer, G., Bähre, A., Gall, F. L., Knackmuss, S. H. J., & Little, M. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.169.1.137 · Cited by 91
Cure of Burkitt's lymphoma in severe combined immunodeficiency mice by T cells, tetravalent CD3 x CD19 tandem diabody, and CD28 costimulation.
Cochlovius, B., Kipriyanov, S. M., Stassar, M. J. J. G., Schuhmacher, J., Benner, A., Moldenhauer, G., & Little, M. (2000) · PubMed · Cited by 91
Bispecific antibodies engage T cells for antitumor immunotherapy
Choi, B. D., Cai, M., Bigner, D. D., Mehta, A. I., Kuan, C.-T., & Sampson, J. H. (2011) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2011.572874 · Cited by 88
Symmetry breaking: bispecific antibodies, the beginnings, and 50 years on.
Riethmüller, G. (2012) · Europe PMC (PubMed Central) · Cited by 85
Bispecific antibody conjugates in therapeutics
Cao, Y., & Lam, L. T. (2003) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00178-3 · Cited by 85
A Bispecific Diabody That Mediates Natural Killer Cell Cytotoxicity Against Xenotransplantated Human Hodgkin’s Tumors
Arndt, M. A. E., Krauß, J., Kipriyanov, S. M., Pfreundschuh, M. G., & Little, M. (1999) · Blood · doi:10.1182/blood.v94.8.2562.420k20_2562_2568 · Cited by 85
Self-citation
The biology of NK cells and their receptors affects clinical outcomes after hematopoietic cell transplantation ( HCT )
Foley, B. A., Felices, M., Cichocki, F. M., Cooley, S., Verneris, M. R., & Miller, J. S. (2014) · Immunological Reviews · doi:10.1111/imr.12157 · Cited by 83
Have we overestimated the benefit of human(ized) antibodies?
Getts, D. R., Getts, M. T., McCarthy, D. P., Chastain, E. M. L., & Miller, S. D. (2010) · mAbs · doi:10.4161/mabs.2.6.13601 · Cited by 85
Treatment of Human B Cell Lymphoma Xenografts with a CD3 × CD19 Diabody and T Cells
Cochlovius, B., Kipriyanov, S. M., Stassar, M. J. J. G., Christ, O., Schuhmacher, J., Strauß, G., Moldenhauer, G., & Little, M. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.165.2.888 · Cited by 79
Advances in bispecific biotherapeutics for the treatment of cancer
May, C., Sapra, P., & Gerber, H. (2012) · Biochemical Pharmacology · doi:10.1016/j.bcp.2012.07.011 · Cited by 81
CD30: an important new target in hematologic malignancies
Deutsch, Y. E., Tadmor, T., Podack, E. R., & Rosenblatt, J. D. (2011) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2011.574761 · Cited by 77
Novel tetravalent and bispecific IgG‐like antibody molecules combining single‐chain diabodies with the immunoglobulin γ1 Fc or CH3 region
Alt, M., Müller, R., & Kontermann, R. E. (1999) · FEBS Letters · doi:10.1016/s0014-5793(99)00782-6 · Cited by 77
Immunology and immunotherapy of human cancer: present concepts and clinical developments
Bremers, A. J. A., & Parmiani, G. (2000) · Critical Reviews in Oncology/Hematology · doi:10.1016/s1040-8428(99)00059-1 · Cited by 77
Treatment of refractory Hodgkin's lymphoma patients with an anti-CD25 ricin A-chain immunotoxin
Schnell, R., Vitetta, E. S., Schindler, J. D., Borchmann, P., Barth, S., Ghetie, V. F., Hell, K., Drillich, S., Diehl, V., & Engert, A. (2000) · Leukemia · doi:10.1038/sj.leu.2401626 · Cited by 75
Targeting CD30/CD30L in Oncology and Autoimmune and Inflammatory Diseases
Oflazoglu, E., Grewal, I. S., & Gerber, H. (2009) · Advances in experimental medicine and biology · doi:10.1007/978-0-387-89520-8_12 · Cited by 74
Single-Domain Antibody–Based and Linker-Free Bispecific Antibodies Targeting FcγRIII Induce Potent Antitumor Activity without Recruiting Regulatory T Cells
Rozan, C., Cornillon, A., Pétiard, C., Chartier, M., Béhar, G., Boix, C., Kerfélec, B., Robert, B., Pèlegrin, A., Chames, P., et al. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-1012 · Cited by 75
Overcoming Instability of Antibody‐Nanomaterial Conjugates: Next Generation Targeted Nanomedicines Using Bispecific Antibodies
Howard, C. B., Fletcher, N. L., Houston, Z. H., Fuchs, A. V., Boase, N. R. B., Simpson, J. D., Raftery, L. J., Ruder, T., Jones, M. L., de Bakker, C. J., et al. (2016) · Advanced Healthcare Materials · doi:10.1002/adhm.201600263 · Cited by 70
Tetraspecific scFv construct provides NK cell mediated ADCC and self-sustaining stimuli via insertion of IL-15 as a cross-linker
Schmohl, J. U., Felices, M., Todhunter, D., Taras, E. P., Miller, J. S., & Vallera, D. A. (2016) · Oncotarget · doi:10.18632/oncotarget.12073 · Cited by 67
Diagnostic, prognostic and therapeutic role of CD30 in lymphoma
Pierce, J. M. R., & Mehta, A. (2016) · Expert Review of Hematology · doi:10.1080/17474086.2017.1270202 · Cited by 67
Bispecific antibodies in haematological malignancies
Viardot, A., & Bargou, R. C. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2018.04.002 · Cited by 69
Effective lysis of lymphoma cells with a stabilised bispecific single‐chain Fv antibody against CD19 and FcγRIII (CD16)
Bruenke, J., Barbin, K., Kunert, S., Lang, P., Pfeiffer, M. M., Stieglmaier, K., NIETHAMMER, D., Stockmeyer, B., Peipp, M., Repp, R., et al. (2005) · British Journal of Haematology · doi:10.1111/j.1365-2141.2005.05414.x · Cited by 63
A phase I study of a HER2/neu bispecific antibody with granulocyte-colony-stimulating factor in patients with metastatic breast cancer that overexpresses HER2/neu
Pullarkat, V., Deo, Y., Link, J., Spears, L., Marty, V., Curnow, R., Groshen, S., Gee, C., & Weber, J. S. (1999) · Cancer Immunology, Immunotherapy · doi:10.1007/s002620050543 · Cited by 55
The novel tribody [(CD20)2xCD16] efficiently triggers effector cell-mediated lysis of malignant B cells
Glorius, P., Baerenwaldt, A., Kellner, C., Staudinger, M., Dechant, M., Stauch, M. B., Beurskens, F. J. M., Parren, P. W. H. I., van de Winkel, J. G. J., Valerius, T., et al. (2012) · Leukemia · doi:10.1038/leu.2012.150 · Cited by 56
Bispecific Antibodies and Trispecific Immunocytokines for Targeting the Immune System Against Cancer
Fournier, P., & Schirrmacher, V. (2012) · BioDrugs · doi:10.1007/s40259-012-0008-z · Cited by 55
Strategies to Augment Natural Killer (NK) Cell Activity against Solid Tumors
Chen, Z., Yang, Y., Liu, L. L., & Lundqvist, A. (2019) · Cancers · doi:10.3390/cancers11071040 · Cited by 53
A recombinant bispecific single‐chain Fv antibody against HLA class II and FcγRIII (CD16) triggers effective lysis of lymphoma cells
Bruenke, J., Fischer, B. E., Barbin, K., Schreiter, K., Wachter, Y., Mahr, K., Titgemeyer, F., Niederweis, M., Peipp, M., Zunino, S. J., et al. (2004) · British Journal of Haematology · doi:10.1111/j.1365-2141.2004.04893.x · Cited by 51
Unlocking the potential of allogeneic Vδ2 T cells for ovarian cancer therapy through CD16 biomarker selection and CAR/IL-15 engineering
Lee, D., Dunn, Z. S., Guo, W., Rosenthal, C. J., Penn, N. E., Yu, Y., Zhou, K., Li, Z., Ma, F., Li, M., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-42619-2 · Cited by 49
Natural Killer Cells: A Review of Biology, Therapeutic Potential and Challenges in Treatment of Solid Tumors
Choucair, K., Duff, J. R., Cassidy, C. S., Albrethsen, M., Kelso, J. D., Lenhard, A., Staats, H., Patel, R., Brunicardi, F. C., Dworkin, L. D., et al. (2019) · Future Oncology · doi:10.2217/fon-2019-0116 · Cited by 49
Targeting T Cells with Bispecific Antibodies for Cancer Therapy
Lum, L. G., & Thakur, A. B. (2011) · BioDrugs · doi:10.2165/11595950-000000000-00000 · Cited by 45
Recent Advances in the Molecular Design and Applications of Multispecific Biotherapeutics
Zhong, X., & D’Antona, A. M. (2021) · Antibodies · doi:10.3390/antib10020013 · Cited by 45
A Novel Bispecific Antibody against Human CD3 and Ephrin Receptor A10 for Breast Cancer Therapy
Taki, S., Kamada, H., Inoue, M., Kazuya, N., Mukai, Y., Higashisaka, K., Yoshioka, Y., Tsutsumi, Y. M., & Tsunoda, S. (2015) · PLoS ONE · doi:10.1371/journal.pone.0144712 · Cited by 43
An Il12-Il2-Antibody Fusion Protein Targeting Hodgkin's Lymphoma Cells Potentiates Activation Of Nk And T Cells For An Anti-Tumor Attack
Jahn, T., Zuther, M., Friedrichs, B., Heuser, C., Guhlke, S., Abken, H., & Hombach, A. A. (2012) · PLoS ONE · doi:10.1371/journal.pone.0044482 · Cited by 42
Bispecifics and antibody–drug conjugates: A positive synergy
Maruani, A. (2018) · Drug Discovery Today Technologies · doi:10.1016/j.ddtec.2018.09.003 · Cited by 42
CD30 as a Therapeutic Target for Lymphoma
Schirrmann, T., Steinwand, M., Wezler, X., ten Haaf, A., Tur, M. K., & Barth, S. (2013) · BioDrugs · doi:10.1007/s40259-013-0068-8 · Cited by 41
Role of the ITAM-Bearing Receptors Expressed by Natural Killer Cells in Cancer
Khlifi, H. M., Guia, S., Vivier, É., & Narni-Mancinelli, É. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.898745 · Cited by 41
Emerging immunotherapies targeting CD30 in Hodgkin's lymphoma
Gerber, H. (2010) · Biochemical Pharmacology · doi:10.1016/j.bcp.2010.01.015 · Cited by 31
Regulation of urokinase plasminogen activator/plasmin- mediated invasion of melanoma cells by the integrin vitronectin receptor αVβ3
Khatib, A., Nip, J., Fallavollita, L., Lehmann, M., Jensen, G. S., & Brodt, P. (2000) · International Journal of Cancer · doi:10.1002/1097-0215(200002)9999:9999 · Cited by 15
Killing the Invaders: NK Cell Impact in Tumors and Anti-Tumor Therapy
Molgora, M., Cortez, V. S., & Colonna, M. (2021) · Cancers · doi:10.3390/cancers13040595 · Cited by 30
Anti- CD16/CD30 Bispecific Antibodies as Possible Treatment for Refractory Hodgkin's Disease
Hartmann, F., Renner, C., Jung, W. E., & Pfreundschuh, M. (1998) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428199809059232 · Cited by 30
Self-citation
Targeting natural killer cells: from basic biology to clinical application in hematologic malignancies
Shang, J., Hu, S., & Wang, X. (2024) · Experimental Hematology and Oncology · doi:10.1186/s40164-024-00481-y · Cited by 29
New drugs in the treatment of Hodgkin’s disease
Borchmann, P., Schnell, R., Diehl, V., & Engert, A. (1998) · Annals of Oncology · doi:10.1093/annonc/9.suppl_5.s103 · Cited by 28
Monoclonal Antibodies
Geskin, L. J. (2015) · Dermatologic Clinics · doi:10.1016/j.det.2015.05.015 · Cited by 29
Current strategies of antibody‐based treatment in Hodgkin's disease
Schnell, R., Borchmann, P., Schulz, H., & Engert, A. (2002) · Annals of Oncology · doi:10.1093/annonc/13.s1.57 · Cited by 27
Dual anti-idiotypic purification of a novel, native-format biparatopic anti-MET antibody with improved in vitro and in vivo efficacy
Godar, M., Morello, V., Sadi, A., Hultberg, A., Jonge, N. D., Basilico, C., Hanssens, V., Saunders, M. J., Lambrecht, B. N., Khattabi, M. E., et al. (2016) · Scientific Reports · doi:10.1038/srep31621 · Cited by 28
Therapeutic Targets of the TNF Superfamily
Grewal, I. S. (2009) · Advances in experimental medicine and biology · doi:10.1007/978-0-387-89520-8 · Cited by 26
Pharmacokinetic–pharmacodynamic relationships of the bispecific antibody MDX-H210 when administered in combination with interferon gamma: a multiple-dose phase-I study in patients with advanced cancer which overexpresses HER-2/neu
Lewis, L. D., Cole, B. F., Wallace, P. K., Fisher, J. L., Waugh, M., Guyre, P. M., Fanger, M. W., Curnow, R. T., Kaufman, P. A., & Ernstoff, M. S. (2001) · Journal of Immunological Methods · doi:10.1016/s0022-1759(00)00355-0 · Cited by 26
Immunotherapy as a Turning Point in the Treatment of Acute Myeloid Leukemia
Aureli, A., Marziani, B., Sconocchia, T., Principe, M. I. D., Buzzatti, E., Pasqualone, G., Venditti, A., & Sconocchia, G. (2021) · Cancers · doi:10.3390/cancers13246246 · Cited by 25
Human CD30: Structural implications from epitope mapping and modeling studies
Dong, L., Hülsmeyer, M., Dürkop, H., Hansen, H. P., Schneider‐Mergener, J., Ziegler, A., & Uchańska‐Ziegler, B. (2003) · Journal of Molecular Recognition · doi:10.1002/jmr.605 · Cited by 25
Retargeting T cells and immune effector cells with bispecific antibodies
Lum, L. G., & Davol, P. A. (2005) · Cancer chemotherapy and biological response modifiers · doi:10.1016/s0921-4410(04)22013-0 · Cited by 25
CD30 and CD30-Targeted Therapies in Hodgkin Lymphoma and Other B cell Lymphomas
Bhatt, G., Maddocks, K. J., & Christian, B. A. (2016) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-016-0345-y · Cited by 23
Anti‐CD30‐IL‐12 antibody‐cytokine fusion protein that induces IFN‐γ secretion of T cells and NK cell‐mediated lysis of Hodgkin's lymphoma‐derived tumor cells
Heuser, C., Diehl, V., Abken, H., & Hombach, A. A. (2003) · International Journal of Cancer · doi:10.1002/ijc.11279 · Cited by 23
Initiation of humoral and cellular immune responses in patients with refractory Hodgkin's disease by treatment with an anti-CD16/CD30 bispecific antibody
Renner, C., Hartmann, F., Jung, W. E., Deisting, C., Juwana, M., & Pfreundschuh, M. G. (2000) · Cancer Immunology Immunotherapy · doi:10.1007/s002620050617 · Cited by 23
Self-citation
New Perspectives in Treating Acute Myeloid Leukemia: Driving towards a Patient-Tailored Strategy
Andreozzi, F., Massaro, F., Wittnebel, S., Spilleboudt, C., Lewalle, P., & Salaroli, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23073887 · Cited by 22
Clinical perspectives of bispecific antibodies in cancer
GAST, G. C. D., van de Winkel, J. G. J., & Bast, B. J. E. G. (1997) · Cancer Immunology Immunotherapy · doi:10.1007/s002620050412 · Cited by 22
Cellular Targeting of Bispecific Antibody-Functionalized Poly(ethylene glycol) Capsules: Do Shape and Size Matter?
Song, D., Cui, J., Ju, Y., Faria, M., Sun, H., Howard, C. B., Thurecht, K. J., & Caruso, F. (2019) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.9b10304 · Cited by 21
Anti‐CD30‐scFv‐Fc‐IL‐2 antibody‐cytokine fusion protein that induces resting NK cells to highly efficient cytolysis of Hodgkin's lymphoma derived tumour cells
Heuser, C., Guhlke, S., Matthies, A., Bender, H., Barth, S., Diehl, V., Abken, H., & Hombach, A. A. (2004) · International Journal of Cancer · doi:10.1002/ijc.20098 · Cited by 20
Natural ligands and antibody-based fusion proteins: harnessing the immune system against cancer
Vyas, M., Koehl, U., Hallek, M. J., & von Strandmann, E. P. (2013) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2013.10.006 · Cited by 20
A trivalent anti-erbB2/anti-CD16 bispecific antibody retargeting NK cells against human breast cancer cells
Xie, Z., Shi, M., Feng, J., Yu, M., Sun, Y., Shen, B., & Guo, N. (2003) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2003.09.211 · Cited by 20
Simultaneous targeting of IL2 and IL12 to Hodgkin's lymphoma cells enhances activation of resting NK cells and tumor cell lysis
Hombach, A. A., Heuser, C., & Abken, H. (2005) · International Journal of Cancer · doi:10.1002/ijc.20829 · Cited by 20
Current and future immunotherapeutic approaches in Hodgkin lymphoma
Bröckelmann, P. J., Borchmann, P., & Engert, A. (2016) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2016.1185789 · Cited by 19
Treatment of relapsed Hodgkin’s disease: Strategies and prognostic factors
Canellos, G. P. (1998) · Annals of Oncology · doi:10.1093/annonc/9.suppl_5.s91 · Cited by 19
Without prior stimulation, tumor-associated lymphocytes from malignant effusions lyse autologous tumor cells in the presence of bispecific antibody HEA125xOKT3.
Strauß, G., Gückel, B., Wallwiener, D. R., & Moldenhauer, G. (1999) · PubMed · Cited by 17
The pharmacokinetics of the bispecific antibody MDX-H210 when combined with interferon gamma-1b in a multiple-dose phase I study in patients with advanced cancer
Lewis, L. D., Beelen, A. P., Cole, B. F., Wallace, P. K., Fisher, J. L., Waugh, M., Kaufman, P. A., & Ernstoff, M. S. (2002) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-002-0424-8 · Cited by 16
Bi-Specific Antibodies in Cancer Therapy
Wang, H., Liu, Y., Wei, L., & Guo, Y. (2002) · Advances in experimental medicine and biology · doi:10.1007/0-306-46817-4_32 · Cited by 15
CD30 as a therapeutic target in adult haematological malignancies: Where are we now?
Veyri, M., Spano, J., Bras, F. L., Marcelin, A., & Todesco, È. (2023) · British Journal of Haematology · doi:10.1111/bjh.18841 · Cited by 14
Immunotherapies for Hodgkin's lymphoma
Kasamon, Y. L., & Ambinder, R. F. (2007) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2007.10.001 · Cited by 13
Method for the preparation of bispecific F(ab′)2μ fragments from mouse monoclonal antibodies of the immunoglobulin M class and characterization of the fragments
Morimoto, K., & Inouye, K. (1999) · Journal of Immunological Methods · doi:10.1016/s0022-1759(99)00007-1 · Cited by 13
Antibodies and antibody‐drug conjugates in the treatment of H odgkin lymphoma
Eichenauer, D. A., & Engert, A. (2014) · European Journal Of Haematology · doi:10.1111/ejh.12347 · Cited by 12
Modeling Natural Killer Cell Targeted Immunotherapies
Lopez‐Lastra, S., & Santo, J. P. D. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00370 · Cited by 13
A novel recombinant bispecific single-chain antibody, bscWue-1 × CD3, induces T-cell-mediated cytotoxicity towards human multiple myeloma cells
Hönemann, D., Kufer, P., Rimpler, M., Chatterjee, M., Friedl, S., Riecher, F., Bommert, K., Dörken, B., & Bargou, R. C. (2004) · Leukemia · doi:10.1038/sj.leu.2403264 · Cited by 11
Immunotherapy of Hodgkin's lymphoma
Borchmann, P., Schnell, R., & Engert, A. (2005) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2005.00471.x · Cited by 11
Autologous transplantation in relapsed and refractory Hodgkin's disease
Josting, A. (2005) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2005.00468.x · Cited by 11
Drug development for recurrent and refractory classical Hodgkin lymphoma
Wildes, T. M., & Bartlett, N. L. (2009) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190902756586 · Cited by 11

Authors: Hartmann, F., Renner, C., Jung, W., Deisting, C., Juwana, M., Eichentopf, B., Kloft, M., & Pfreundschuh, M.
Affiliations: Universitätsklinikum des Saarlandes (DE)
ORCID: Hartmann, Frank
Renner, Christoph
Jung, Wolfram
Pfreundschuh, Michael
Venue: Blood
Publisher: American Society of Hematology
Published: 1997-03-15
Volume: 89
Issue: 6
Pages: 2042-2047
ISSN: 0006-4971 (ISSN-L)
1528-0020
DOI: 10.1182/blood.v89.6.2042
OpenAlex: W1539079695
Cited by: 149
References: 29
Citations by year: 2026: 1 · 2025: 2 · 2024: 4 · 2023: 3 · 2022: 4 · 2021: 4 · 2020: 3 · 2019: 3 · 2018: 5 · 2017: 4 · 2016: 8 · 2015: 5 · 2014: 5 · 2013: 6 · 2012: 7
FWCI: 5.83
Type: journal article
Language: en
Open access: closed
Locations: Blood (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
Life Sciences › Immunology and Microbiology › Immunology › Immune Cell Function and Interaction
Keywords: refractory Hodgkin lymphoma, bispecific antibodies, CD16, CD30, NK cell activation, Fc gamma receptor III, immunotherapy, maximum tolerated dose, human anti-mouse antibodies, immunogenicity, allergic reactions, treatment response
MeSH terms: Adolescent, Adult, Antibodies, Monoclonal, Female, Hodgkin Disease, Humans, Male, Middle Aged, Remission Induction, Lymphocyte Subsets, Receptors, IgG, Ki-1 Antigen, Antibodies, Bispecific, Lymphocyte Count

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Treatment of Refractory Hodgkin's Disease With an Anti-CD16/CD30 Bispecific Antibody

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks